CXCL12 and hepatocellular carcinoma: Here, we identified that the adoptive transfer of CXCR4+ B cells combined with exogenous CXCL12 treatment could elevate NK cells and macrophage infiltration to suppress mouse HCC development via ADCC response, which provides a promising immunotherapy option for clinical HCC treatment.